"Half-Life" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.
| Descriptor ID |
D006207
|
| MeSH Number(s) |
G01.910.405
|
| Concept/Terms |
Half-Life- Half-Life
- Half Life
- Half-Lifes
- Halflife
- Halflifes
|
Below are MeSH descriptors whose meaning is more general than "Half-Life".
Below are MeSH descriptors whose meaning is more specific than "Half-Life".
This graph shows the total number of publications written about "Half-Life" by people in this website by year, and whether "Half-Life" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 4 | 4 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 7 | 7 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 3 | 3 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 3 | 3 |
| 2019 | 0 | 3 | 3 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Half-Life" by people in Profiles.
-
Belaghzal H, Borrman T, Stephens AD, Lafontaine DL, Venev SV, Weng Z, Marko JF, Dekker J. Liquid chromatin Hi-C characterizes compartment-dependent chromatin interaction dynamics. Nat Genet. 2021 03; 53(3):367-378.
-
Liu Y, Liang X, Zou Y, Peng Y, McClements DJ, Hu K. Resveratrol-loaded biopolymer core-shell nanoparticles: bioavailability and anti-inflammatory effects. Food Funct. 2020 May 01; 11(5):4014-4025.
-
Mauger DM, Cabral BJ, Presnyak V, Su SV, Reid DW, Goodman B, Link K, Khatwani N, Reynders J, Moore MJ, McFadyen IJ. mRNA structure regulates protein expression through changes in functional half-life. Proc Natl Acad Sci U S A. 2019 11 26; 116(48):24075-24083.
-
Yeom J, Guimaraes PPG, Ahn HM, Jung BK, Hu Q, McHugh K, Mitchell MJ, Yun CO, Langer R, Jaklenec A. Chiral Supraparticles for Controllable Nanomedicine. Adv Mater. 2020 Jan; 32(1):e1903878.
-
Johnson ER, Taylor AR, Boothe DM, Gray-Edwards HL, Winter RL, Martin DR. Pharmacokinetics of a commercially available product and a compounded formulation of extended-release levetiracetam after oral administration of a single dose in cats. Am J Vet Res. 2019 Oct; 80(10):950-956.
-
Santoni M, Massari F, Piva F, Carrozza F, Di Nunno V, Cimadamore A, Martignetti A, Montironi R, Battelli N. Tivozanib for the treatment of renal cell carcinoma. Expert Opin Pharmacother. 2018 Jun; 19(9):1021-1025.
-
Ganz DE, Sexton-Stallone B, Brackett EL, Forbes NS. Tissue transport affects how treatment scheduling increases the efficacy of chemotherapeutic drugs. J Theor Biol. 2018 02 07; 438:21-33.
-
Smith HL, Saia G, Lobikin M, Tiwari T, Cheng SC, Molrine DC. Characterization of serum anti-diphtheria antibody activity following administration of equine anti-toxin for suspected diphtheria. Hum Vaccin Immunother. 2017 11 02; 13(11):2738-2741.
-
Zhou C, Molinie B, Daneshvar K, Pondick JV, Wang J, Van Wittenberghe N, Xing Y, Giallourakis CC, Mullen AC. Genome-Wide Maps of m6A circRNAs Identify Widespread and Cell-Type-Specific Methylation Patterns that Are Distinct from mRNAs. Cell Rep. 2017 Aug 29; 20(9):2262-2276.
-
Landersdorfer CB, Findling RL, Frazier JA, Kafantaris V, Kirkpatrick CM. Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics. Clin Pharmacokinet. 2017 01; 56(1):77-90.